Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Lindsay H. Burns"'
Autor:
Hoau-Yan Wang, Zhe Pei, Kuo-Chieh Lee, Boris Nikolov, Tamara Doehner, John Puente, Nadav Friedmann, Lindsay H. Burns
Publikováno v:
Frontiers in Aging, Vol 4 (2023)
Introduction: Implicated in both aging and Alzheimer’s disease (AD), mammalian target of rapamycin (mTOR) is overactive in AD brain and lymphocytes. Stimulated by growth factors such as insulin, mTOR monitors cell health and nutrient needs. A small
Externí odkaz:
https://doaj.org/article/fbf6b873265e47139da705dfa19e68eb
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 18, p 13927 (2023)
Simufilam is a novel oral drug candidate in Phase 3 clinical trials for Alzheimer’s disease (AD) dementia. This small molecule binds an altered form of filamin A (FLNA) that occurs in AD. This drug action disrupts FLNA’s aberrant linkage to the
Externí odkaz:
https://doaj.org/article/ab956b87a59c4e17a31e3090a28cc4bf
Autor:
Lindsay H Burns, Tamara Doehner, John Puente, Brian Beck, Yaneicy Gonzalez‐Rojas, Evelyn Lopez‐Brignoni, Boris Nikolov, Hoau‐Yan Wang, Zhe Pei, Antonio Hernandez, Carrie A Crowley, Nadav Friedmann
Publikováno v:
Alzheimer's & Dementia. 17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61c849d873a19181f197589c4ae21435
https://doi.org/10.1002/alz.054395
https://doi.org/10.1002/alz.054395
Publikováno v:
Alzheimer's & Dementia. 17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5e5e0691dc5d12e3e59b235d894c82f
https://doi.org/10.1002/alz.054385
https://doi.org/10.1002/alz.054385
Autor:
Brian Beck, Yaneicy Gonzalez Rojas, John Puente, Carrie A Crowley, Kuo-Chieh Lee, Evelyn Lopez-Brignoni, Tamara Doehner, Hoau-Yan Wang, Patrick Sciara, Boris Nikolov, Nadav Friedmann, Remi Barbier, Lindsay H. Burns, George Ben Thornton, Jeffrey L. Cummings, Zhe Pei
BACKGROUND Simufilam is a first-in-class drug candidate targeting altered filamin A, a proteopathy in Alzheimer’s disease. The primary objective of this Phase 2 clinical trial was to evaluate the effects of simufilam on cerebrospinal fluid (CSF) bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e1101c8f80628d9a2a703194cbbbadf
https://doi.org/10.21203/rs.3.rs-249858/v1
https://doi.org/10.21203/rs.3.rs-249858/v1
Autor:
N. Friedmann, Zhe Pei, Evelyn Lopez-Brignoni, Carrie A Crowley, Kuo-Chieh Lee, M. R. Marsman, Remi Barbier, Boris Nikolov, Hoau-Yan Wang, Lindsay H. Burns
Publikováno v:
The journal of prevention of Alzheimer's disease. 7(4)
BACKGROUND: The most common dementia worldwide, Alzheimer’s disease is often diagnosed via biomarkers in cerebrospinal fluid, including reduced levels of Aβ1–42, and increases in total tau and phosphorylated tau-181. Here we describe results of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7fa457568d82a68d03124d9c16abb01
https://pubmed.ncbi.nlm.nih.gov/32920628
https://pubmed.ncbi.nlm.nih.gov/32920628
Autor:
Michael M. Crowley, Michael Zamloot, Nadav Friedmann, Shawn A. Kucera, Remi Barbier, Lindsay H. Burns
Publikováno v:
Journal of Opioid Management. 14:429-436
Objective: These in vitro studies compared abuse-deterrent properties of REMOXY ER (extended-release oxycodone), a novel, high-viscosity gel formulation, versus the two currently marketed ER oxycodone formulations. Methods: Tampering methods were tai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff8b93c2db98a98674b4084ae240ca7
https://doi.org/10.5055/jom.2018.0475
https://doi.org/10.5055/jom.2018.0475
Publikováno v:
Journal of Opioid Management. 14:437-443
Objective: This study examined the nasal abuse deterrence of REMOXY ER, a novel high-viscosity extended-release oxycodone formulation. Design: An Institutional Review Board-approved, single-center, randomized, double-blind, placebo, and active-contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bbe808afc03e37439af2376c3eba520
https://doi.org/10.5055/jom.2018.0476
https://doi.org/10.5055/jom.2018.0476
Autor:
Hoau-Yan Wang, Lindsay H Burns
Publikováno v:
PLoS ONE, Vol 4, Iss 1, p e4282 (2009)
Chronic morphine causes the mu opioid receptor (MOR) to switch its coupling from Gi/o to Gs, resulting in excitatory signaling via both Galphas and its Gbetagamma dimer. Ultra-low-dose naloxone (NLX) prevents this switch and attenuates opioid toleran
Externí odkaz:
https://doaj.org/article/c1ca0630d8494c79a706a4a5ef23216a
Publikováno v:
PLoS ONE, Vol 3, Iss 2, p e1554 (2008)
Ultra-low-dose opioid antagonists enhance opioid analgesia and reduce analgesic tolerance and dependence by preventing a G protein coupling switch (Gi/o to Gs) by the mu opioid receptor (MOR), although the binding site of such ultra-low-dose opioid a
Externí odkaz:
https://doaj.org/article/989540d8500048f5a02b7c9aeefbf9e2